Everyone realizes Todzun/Van was here bashing ARNA at $1.21 and pumping VVUS at $30? So why are you still here?
Contrave has been sold in US many years already only scripts affected are generics.
You meant Jack out traded many shorts didn't you? Sure you did.
Whatever happened to neo17a? Looks like he disappeared just as Contrave was FDA approved with black box warnings.
Jim are you angry because Jack out traded you? Many longs here did the same.
Contrave has been sold in US many years already as generic drugs and therefore won't be taking any scripts away. Sure you already knew that.
Jack was very smart. You should have sold too. Maybe next time?
US medical community launched Contrave years ago as generic drugs during a period when US obesity rates tripled. No thanks I'll stick with the only new obesity drug FDA approved since 1999- Belviq.
Belviq is the one and only brand new (non reformulated generic) obesity drug approved by the FDA since 1999. Bet you already knew that.
There is no real offer for VVUS as Aspen does not have the shares to complete the deal instead lilely pumped VVUS yesterday for a quick buck and got out. VVUS still closed below $5. Most VVUS longs like Van bought above $19 btw.
In the form of 2 generic drugs. Smart investors know there is nothing new here with reformulated Contrave, and OREX will likely suffer the same fate as VVUS did with trying to market their also outdated generic combo Qsymia. June 10th looks to be time to sell or even a great opportunity to short OREX with a REMS FDA approval announcement pending.
The time to have bought OREX was back in the $1's January 2012. Those investors mostly non retail institutions are looking to get out within next 2 weeks when wall street sells the FDA news.
Problem with your theory is "Contrave" has been on the market already for many years in the form of generic drugs so nobody invested here with Belviq is deeply worried. Besides "Belphen" will be the combo of choice and is already starting to be prescribed here in US wit generic phen added to Belviq. Belviq responders have shown to lose on average 11% weight on a single agent drug. ARNA did extensive studies including CVOT on 8,000 people during trials.
Another problem with your theory is you are posting to longs holding major profits while over 40 million shares short are still riding losses from early 2012 including 19 million shares shorted under $3. Do you actually think someone will sell Tuesday because of your post? You are only awakening buyers... good luck covering.
No more milestones Van? I can see why you are continuously on the wrong side of this trade.
Fred doesn't yet realize many longs already bought under $2 after the original deal with Eisai and again under $5 last November.
Funny that the only ones here complaining about ARNA being corrupt are the underwater shorts. Right Fred?